Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1331-1341

  Troke, Philip J F ^a   Lewis, Marilyn ^a   Simpson, Paul ^a   Gore, Katrina ^a   Hammond, Jennifer ^b   Craig, Charles ^a   Westby, Mike ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; FILIBUVIR; NONSTRUCTURAL PROTEIN 5B;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION; WILD TYPE;

ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CLONING, MOLECULAR; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INHIBITORY CONCENTRATION 50; METHIONINE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; PYRONES; REPLICON; RNA REPLICASE; TRANSFECTION; TRIAZOLES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84857186976     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05611-11     Document Type: Article

References (24)

1. Cooper C, et al. 2009. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol. 51:39-46.
2. Fried MW, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
3. Gaudieri S, et al. 2009. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49: 1069-1082.
4. Graham EJ, et al. 2011. Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals. J. Virol. Methods 174:153-157.
5. Guedj J, Rong L, Dahari H, Perelson AS. 2010. A perspective on modelling hepatitis C virus infection. J. Viral Hepat. 17:825-833.
6. Hadziyannis SJ, et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
7. Kuntzen T, et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
8. Lau DT, et al. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
9. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int. 29(Suppl. 1):74-81.
10. Lemon SM, et al. 2010. Development of novel therapies for hepatitis C. Antiviral Res. 86:79-92.
11. Le Pogam S, et al. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216. (Pubitemid 351753583)
12. Love RA, et al. 2003. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77:7575-7581. (Pubitemid 36734527)
13. Manns MP, et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. (Pubitemid 32913521)
14. Middleton T, et al. 2007. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J. Virol. Methods 145:137-145. (Pubitemid 47332699)
15. Nomenclature Committee of IUB. 1985. Nomenclature Committee of IUB (NC-IUB) and IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCNB). Newsletter 1985. Biol. Chem. Hoppe-Seyler 366:3-8.
16. Pawlotsky JM. 2011. The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140:746-754.
17. Rong L, Dahari H, RibeiroRM,Perelson AS. 2010. Rapid emergence of protease inhibitor resistance in hepatitisCvirus. Sci. Transl. Med. 2:30ra32.
18. Sarrazin C, et al. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. (Pubitemid 46677938)
19. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462.
20. Shi ST, et al. 2008. In vitro resistance study of AG-021541, a novel non-nucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52:675-683. (Pubitemid 351170844)
21. Shi ST, et al. 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 53:2544-2552.
22. Soriano V, Peters MG, Zeuzem S. 2009. New therapies for hepatitis C virus infection. Clin. Infect. Dis. 48:313-320.
23. Wagner F, et al. 2011. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1 infected patients. Hepatology 54:50-59.
24. World Medical Association. 2011. World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/.